Imaging tests performed for another reason, is the most commonly reported in the literature, this was an atypical case of ganglioneuroma. Its atypical features included its location, because only 20–30% of cases occur in the adrenal gland; age at presentation, as these are tumors that may occur in any age group, but more than 80% are reported in patients under 40 years of age, and more than half of these are younger than 20 years; and functionality, because only 30% of ganglioneuromas secrete plasma and urinary catecholamines, and symptoms related to hormone hypersecretion rarely occur in such cases. In this case, endocrine tests showed high levels of chromogranin A, VMA, normetanephrine, and dopamine in the urine. Adrenal mass biopsy should not be performed at the least suspicion of pheochromocytoma or without previously ruling out high catecholamine levels, considerations which were transmitted to the gastroenterology department. Imaging tests were inconclusive and so provided no reliable data for establishing the etiology. Only scintigraphy showed in the late control a strong uptake by the mass suggesting adrenergic overexpression.

In this case, hormone and imaging tests not only did not allow us to discriminate between incidentally found adrenal lesions or to make a firm diagnosis, but they also suggested a wrong diagnosis (pheochromocytoma). Pathological examination of the surgical specimen established the final diagnosis of ganglioneuroma.

References

Mubarak AlRamadan*, Sara López Martínez*, Ana María Cerezo Arillob, Francisco Martín Ordóñezc

a Unidad de Endocrinología y Nutrición, Hospital Virgen de la Luz, Cuenca, Spain
b Servicio de Análisis Clínicos, Hospital Virgen de la Luz, Cuenca, Spain
c Servicio de Medicina Nuclear, Hospital Virgen de la Luz, Cuenca, Spain
*Corresponding author.
E-mail address: slopma@hotmail.com (S. López Martínez).

Implication of excess iodine intake in Graves-Basedow-disease

Implicación del aporte excesivo del yodo en la enfermedad de Graves-Basedow

Graves-Basedow disease is the most common cause of hyperthyroidism. As is well known, this is an autoimmune disease in which TSI antibodies (thyroid-stimulating immunoglobulins) stimulate thyroid hormone synthesis and release, provided an adequate amount of iodine is available. The condition may be triggered by an episode of emotional stress, infection, pregnancy or delivery, or an increased iodine intake at a given time.

In clinical history, drugs such as amiodarone, the use of iodinated contrast media, or iodinated salt consumption are usually suspected, but a more comprehensive search is sometimes required.

A 42-year-old female patient with an unremarkable history attended her general practitioner reporting a loss of 12 kg in weight and nervousness during the previous months. Thyroid function tests were requested with the following results: TSH < 0.01 (NR, 0.4–4.0 ng/dL);
but up to 50-60

A test for urinary iodine was requested.

iodine almost daily to heal the wounds caused by scratches.

importance to the fact that she had a cat and used povidone

all drugs and antiseptics she used at home. She had given no

bly due to scratches. The patient was asked to bring with her

monitored. A ward examination revealed skin lesions possi-

surgical treatment was decided upon.

response to drug treatment and severe clinical symptoms,

To Graves-Basedow disease, and because of the lack of

following results: TSH 0.1 and FT4 8.33 ng/dL.

>30 (NR, <1.7 IU/mL).

FT4 3.1, anti-TPO antibodies >1000 IU/mL; and TSI antibodies

after the maximal methimazole dose included: TSH 0.19,

fuse thyroid disease.

A thyroid ultrasound examination was consistent with dif-

otherwise normal.

A thyroid scan showed strong and uniform hyper-uptake.

A thyroid ultrasound examination was consistent with dif-

fuse thyroid disease.

The results of laboratory tests performed three weeks

after the maximal methimazole dose included: TSH 0.19,

FT4 3.1, anti-TPO antibodies >1000 IU/mL; and TSI antibodies

>30 (NR, <1.7 IU/mL).

Tests performed after six weeks on maximum methima-

zole doses with proven treatment compliance found the

following results: TSH 0.1 and FT4 8.33 ng/dL.

Based on a diagnosis of primary hyperthyroidism due
to Graves-Basedow disease, and because of the lack of
response to drug treatment and severe clinical symptoms,
surgical treatment was decided upon.

It was also decided that treatment compliance during
admission for preparation for total thyroidectomy should be
monitored. A ward examination revealed skin lesions possi-
bly due to scratches. The patient was asked to bring with her
all drugs and antiseptics she used at home. She had given no
importance to the fact that she had a cat and used povidone
iodine almost daily to heal the wounds caused by scratches.
A test for urinary iodine was requested.

FT4: 3.28 (NR, 0.89–1.76 ng/dL); and anti-TPO antibod-
ies >1000 (NR, <35 IU/mL). Treatment was started with
methimazole 5 mg every 8 h, which was uptitrated to
60 mg daily due to lack of improvement, and propra-
nolol 40 mg every 8 h. The results of the last laboratory
tests on the above treatment were TSH <0.01 and FT4
6.01 ng/dL. The dosage was increased to 90 mg daily and the
patient was referred to the endocrinology department for
work-up.

The patient reported progressive weight loss for four
months, as well as intense daily palpitations, nervousness,
and insomnia. She was taking iodinated salt and regularly
used a hair dye, but this did not contain iodine. No drug
intake or recent history of use of iodinated contrast media
was found. The use of creams of other topical substances
with high iodine contents was not reported. She was advised
to stop using iodinated salt.

Physical examination findings included: 72.8 kg of weight
(86 kg previously); body mass index, 27 kg/m²; blood pres-
sure, 145/80 mmHg; and heart rate of 100 bpm. The patient
had a bright gaze with minimal lid retraction. No oph-
thalmos was found. Palpation revealed an elastic, nontender
grade II thyroid gland with no nodules. The examination was
otherwise normal.

A thyroid scan showed strong and uniform hyper-uptake.

A thyroid ultrasound examination was consistent with dif-

fuse thyroid disease.

The results of laboratory tests performed three weeks

after the maximal methimazole dose included: TSH 0.19,

FT4 3.1, anti-TPO antibodies >1000 IU/mL; and TSI antibodies

>30 (NR, <1.7 IU/mL).

Tests performed after six weeks on maximum methima-

zole doses with proven treatment compliance found the

following results: TSH 0.1 and FT4 8.33 ng/dL.

Based on a diagnosis of primary hyperthyroidism due
to Graves-Basedow disease, and because of the lack of
response to drug treatment and severe clinical symptoms,
surgical treatment was decided upon.

It was also decided that treatment compliance during
admission for preparation for total thyroidectomy should be
monitored. A ward examination revealed skin lesions possi-
bly due to scratches. The patient was asked to bring with her
all drugs and antiseptics she used at home. She had given no
importance to the fact that she had a cat and used povidone
iodine almost daily to heal the wounds caused by scratches.
A test for urinary iodine was requested.

Lugol, 8 drops every 6 h, and prednisone 60 mg every 24 h
were subsequently added to the treatment. This achieved
control of thyroid hormones before total thyroidectomy,
which was uneventful. Urinary iodine level, reported after
surgery, was >800 μg/mL (NR, 100–200) (Table 1).

The daily iodine requirements for thyroid hormone syn-
thesis are 150 μg. Mean urinary iodine level in the US is
14.5 μg/dL, but up to 50–60 μg/dL in other countries with
a higher intake, such as Iceland.

The thyroid gland has a regulation mechanism that main-
tains normal function even in the presence of excess iodine.
Although the release of T4 and T3 may decrease in the
first 48 h due to decreased iodine organification (the Wolff-
Chaikoff effect), hormone hyperproduction may eventually
result (Jod-Basedow). It is estimated that the amount of
iodine ingested below which thyroid function is not affected
is 500 μg/day.

In areas with an endemic iodine deficiency, hyperthy-
roidism induced by excess iodine intake may occur in

<table>
<thead>
<tr>
<th>Substance</th>
<th>Iodine contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmic drugs</td>
<td>75 mg per 200 mg of drug</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>15 mg/tablet</td>
</tr>
<tr>
<td>Expectorants</td>
<td>6.6 mg/mL</td>
</tr>
<tr>
<td>Iodinated glycerol</td>
<td>134 mg/tablet</td>
</tr>
<tr>
<td>Anti-asthma drugs</td>
<td>10 mg/mL</td>
</tr>
<tr>
<td>Theophylline</td>
<td>60 day⁻¹</td>
</tr>
<tr>
<td>Iodoquinol</td>
<td>10–70 mg/mL</td>
</tr>
<tr>
<td>Amebicides</td>
<td>5–100 mg/mL</td>
</tr>
<tr>
<td>Iodoquinol (1%)</td>
<td>6.4 mg/g</td>
</tr>
<tr>
<td>Cadexomer iodine</td>
<td>12 mg/g</td>
</tr>
<tr>
<td>Iodoquinol (3%)</td>
<td>12 mg/g</td>
</tr>
<tr>
<td>Iodinated glycerol</td>
<td>75–100 mg/mL</td>
</tr>
<tr>
<td>Topical antiseptics</td>
<td>10–100 mg/mL</td>
</tr>
<tr>
<td>Iodoquinol</td>
<td>10–100 mg/mL</td>
</tr>
<tr>
<td>Cadexomer iodine</td>
<td>300–400 mg/mL</td>
</tr>
<tr>
<td>Iodoquinol (1%)</td>
<td>300–400 mg/mL</td>
</tr>
<tr>
<td>Iodoquinol (3%)</td>
<td>300–400 mg/mL</td>
</tr>
<tr>
<td>Cadexomer iodine</td>
<td>300–400 mg/mL</td>
</tr>
<tr>
<td>Other</td>
<td>600–1000 mg of seaweed (variable)</td>
</tr>
<tr>
<td>Seaweed</td>
<td>720 μg/application</td>
</tr>
</tbody>
</table>

Table 1 Changes over time in thyroid function tests.

<table>
<thead>
<tr>
<th>Test</th>
<th>Baseline</th>
<th>Week 6</th>
<th>Week 12</th>
<th>Week 18</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH</td>
<td>NR 0.4</td>
<td>&lt;0.01</td>
<td>&lt;0.01</td>
<td>0.19</td>
<td>0.10</td>
</tr>
<tr>
<td>FT4</td>
<td>0.89–1.7 ng/dL</td>
<td>3.82</td>
<td>6.01</td>
<td>3.1</td>
<td>8.33</td>
</tr>
<tr>
<td>FT3</td>
<td>1.8–4.2 mg/dL</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>Anti-TPO Ab</td>
<td>&lt;35 IU/mL</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>TSI</td>
<td>&lt;1.7 IU/mL</td>
<td>&gt;30</td>
<td>&gt;30</td>
<td>&gt;30</td>
<td>&gt;30</td>
</tr>
<tr>
<td>Urinary iodine</td>
<td>100–200 μg/mL</td>
<td>&gt;800</td>
<td>&gt;800</td>
<td>&gt;800</td>
<td>&gt;800</td>
</tr>
</tbody>
</table>

Table 2 Iodine contents in different substances.
patients with a multinodular thyroid gland, autonomous nodules, or latent Graves-Basedow disease due to increased thyroid hormone production and release. Its incidence is 1.7%.

Areas with adequate iodine intake have a low incidence of hyperthyroidism induced by excess iodine intake.

Euthyroid patients with some prior episode of postpartum thyroiditis, type 2 amiodarone-induced thyrotoxicosis, or interferon-induced thyroid dysfunction are more susceptible to develop hyperthyroidism due to excess iodine intake (up to 20%), as are patients with multinodular thyroid, autonomous nodules, or diffuse goiter. In the latter, the prevalence ranges from 3.5% to 21% depending on iodine exposure.

Iodine intake may set the course in patients with Graves-Basedow disease, because a slight increase in dietary iodine results in a greater frequency of hyperthyroidism and a decreased efficacy of antithyroid treatment. In addition, in iodine-deficient areas, the response to antithyroid agents is better and lower doses are required for hormone control.

It is therefore essential to consider the potential factors leading to excess iodine intake when faced with difficult to control Graves-Basedow disease (Table 2).

In the case of our patient, the course of hyperthyroidism led us to decide upon a definitive treatment. The clinical condition of the patient and the course of events prevented us from detecting excess iodine intake before surgery or a potential improvement after the removal of povidone iodine, but a more satisfactory response to drug treatment could have been expected in the absence of excess iodine intake.

Primary hyperparathyroidism and acute pancreatitis

Hiperparatiroidismo primario y pancreatitis aguda

Sir,

Primary hyperparathyroidism (PHPT) is the leading cause of hypercalcemia in a hospital setting and has an incidence of 1–2 cases/1000 admissions. The biochemical and clinical manifestations or PHPT are related to increased PTH levels or hypercalcemia. In addition, associated syndromes such as high blood pressure, peptic ulcer, chondrocalcinosis, or acute pancreatitis (AP), whose relationship to phosphate and calcium metabolism disorders have not been fully elucidated, may occur.

We report a 26-year-old male patient with a history of allergy to erythromycin, a smoker of 20 cigarettes daily who was diagnosed in February 2010 with AP of unknown etiology based on Ranson criteria. The etiological study was performed on an outpatient basis. Laboratory test results included: serum calcium 11.3 mg/dL, corrected calcium 10.5 mg/dL, urinary calcium 29 mg/dL, phosphate 2.6 mg/dL, and PTH 333 pg/mL. PHPT was suspected, and imaging tests were requested to discover its location. MRI and scintigraphy with Tc-99 showed images consistent with a right upper parathyroid adenoma. No personal or family history of tumors related to multiple endocrine neoplasia syndrome was found. In February 2011, right upper parathyroidectomy was performed with selective access. The baseline intraoperative PTH level was 376 pg/mL, but its value decreased to 26 pg/mL after resection. The pathological report confirmed the diagnosis of parathyroid adenoma. In the early postoperative period, the patient experienced severe abdominal pain associated with nausea, vomiting, and abdominal distention. Laboratory tests showed that at that time an amylase level of 500 IU/L and a calcium level of 8.2 mg/dL. The abdominal ultrasound performed showed no changes. AP was diagnosed based on clinical signs and symptoms, and showed a successful course with conservative treatment. At subsequent visits, the patient

References


Sorra Civantos, Emilia Canovas, Juan José Gorgojo, Gloria Cánovas, Azucena Rodríguez

a Endocrinología y Nutrición, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
b Endocrinología y Nutrición, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

Corresponding author.
E-mail address: zulemaciv@hotmail.com (S. Civantos).